Uncategorized
Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3
Topline Phase 3 results of survodutide—licensed to Boehringer Ingelheim from Zealand Pharma—are more comparable to Novo Nordisk’s Wegovy than to Eli Lilly’s Zepbound, William Blair analysts said on Tuesday.